Related Experiment Video
Updated: Mar 7, 2026

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
Published on: October 6, 2016
Cardiovascular Complications of HIV Infection
1Weill Cornell Medicine, New York, NY, USA.
Insights
Cardiovascular disease (CVD) risk calculators need validation for HIV-infected individuals. HIV infection may be an independent CVD risk factor, influenced by immune activation and antiretroviral therapy.
Area of Science:
- Infectious Diseases
- Cardiology
- Public Health
Background:
- Individuals with human immunodeficiency virus (HIV) face a higher risk of cardiovascular disease (CVD).
- Current CVD risk calculators are not adequately validated for the HIV-infected population.
- Chronic immune activation and inflammation are increasingly implicated in CVD pathogenesis among those with HIV.
Purpose of the Study:
- To review the challenges in assessing CVD risk in HIV-infected individuals.
- To discuss the impact of antiretroviral therapy (ART) on lipid profiles and CVD risk.
- To highlight the need for updated risk assessment strategies in this population.
Main Methods:
- Summary of a presentation by Marshall J. Glesby, MD, PhD.
- Discussion based on expert opinion and emerging evidence.
- Focus on clinical considerations for HIV care providers.
Main Results:
- Standard CVD risk calculators may underestimate risk in HIV-infected patients.
- ART can affect lipid profiles, complicating risk assessment.
- HIV itself may be an independent risk factor for CVD.
Conclusions:
- There is a critical need for validated CVD risk assessment tools for HIV-infected individuals.
- Clinical decisions regarding statin therapy require careful consideration of HIV-specific factors.
- Further research is needed to understand and mitigate CVD risk in the context of HIV infection.
Abstract:
HIV-infected individuals are at increased risk for cardiovascular events. Widely used cardiovascular disease (CVD) risk calculators to determine indications for statin treatment are not well validated for use in the HIV-infecte population. Some experts advocate including HIV infection as an independent risk factor for CVD. The effects of antiretroviral therapy on lipid profiles and the potentially increased risk for cardiovascular events must be taken into account when selecting treatment for HIV-infected individuals. There is increasing evidence that chronic immune activation and inflammation play a role in the pathogenesis of CVD in the context of HIV infection. This article summarizes a presentation by Marshall J. Glesby, MD, PhD, at the Ryan White HIV/AIDS Program Clinical Care Conference held in New Orleans, Louisiana, in December 2015.
More Related Videos
10:04Quantification of Cerebral Vascular Architecture using Two-photon Microscopy in a Mouse Model of HIV-induced Neuroinflammation
Published on: January 12, 2016
05:53Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
Related Concept Videos
Hemodialysis II: Procedure and Complications
Rheumatic Heart Disease I: Introduction
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiovascular Drugs: Classification based on Therapeutic Indications
Sexually Transmitted Infections